Trazimera 150 mg powder for concentrate for solution for infusion Trazimera 420 mg powder for concentrate for solution for infusion
What Trazimera is and what it is used for
Trazimera contains the active ingredient trastuzumab, which is a monoclonal antibody. Monoclonal antibodies attach to specific proteins or antigens. Trastuzumab is designed to bind selectively to an antigen called human epidermal growth factor receptor 2 ( HER2 ). HER2 is found in large quantities on the surface of certain cancer cells and then stimulates cell growth. When Trazimera binds to HER2, the growth of the cancer cells is stopped and this leads to their death.
Your doctor may prescribe Trazimera to treat breast and stomach cancer if:
- you have early breast cancer with high levels of protein et HER2.
- you have metastatic breast cancer (breast cancer that has spread beyond the original tumor) with high levels of HER2. Trazimera can be prescribed in combination with the chemotherapy drugs paclitaxel or docetaxel as first-line treatment for metastatic breast cancer, or it can be prescribed as the only treatment if other treatments have failed. It is also used in combination with medicines called aromatase inhibitors to treat patients with high levels of HER2 and hormone receptor-positive metastatic (spread) breast cancer (cancer that is sensitive to the presence of female sex hormones).
- you have metastatic gastric cancer with high levels of HER2 when it is used in combination with capecitabine or 5-fluorouracil and cisplatin.
What you need to know before you receive Trazimera
Do not use Trazimera if
- you are allergic to trastuzumab, murine (mouse) protein, or any of the other ingredients of this medicine (listed in section 6).
- you have severe breathing problems at rest due to your cancer or if you need oxygen therapy.
Warnings and precautions
Your doctor will closely monitor your treatment.
Control of the heart
Treatment with Trazimera alone or in combination with a taxane may affect the heart, especially if you have previously been treated with an anthracycline (taxanes and anthracyclines are two other types of medicine used to treat cancer). Effects can be moderate to severe and some patients have died. Your heart function will therefore be checked before and during treatment (every three months) and after (up to two to five years) treatment with Trazimera. If you develop signs of heart failure (insufficient pumping of blood from the heart), your heart function may be checked more frequently (every six to eight weeks). You may then receive treatment for heart failure or possibly need to stop treatment with Trazimera.
Talk to your doctor, pharmacist, or nurse before you are given Trazimera if:
- you have had heart failure, coronary artery disease, valvular heart disease (heart murmur ), or high blood pressure if you have taken or are currently taking medicines for high blood pressure.
- you have previously received or are currently receiving a medicine called doxorubicin or epirubicin (medicines used to treat cancer). These medicines (or other anthracyclines ) can damage the heart muscle and increase the risk of heart problems with Trazimera.
- you suffer from shortness of breath, especially if you are also being treated with taxidermy. Trazimera can cause breathing difficulties, especially when it is given for the first time. This can be more serious if you are already short of breath. Patients with severe breathing difficulties have very rarely died in connection with treatment with Trazimera.
- you have previously received any other cancer treatment.
If you receive Trazimera together with other medicines to treat cancer, such as paclitaxel, docetaxel, an aromatase inhibitor, capecitabine, 5-fluorouracil, or cisplatin, you should also carefully read the package leaflets for these products.
Children and young people
Tamera is not recommended for anyone under 18 years of age.
Other medicines and Trazimera
Tell your doctor, pharmacist, or nurse if you are taking, have recently taken, or might take any other medicines.
It can take up to 7 months for Trazimera to be removed from the body. You should therefore tell the doctor, pharmacist, or nurse that you have been treated with Trazimera if you start any new medication within 7 months of finishing treatment.
Pregnancy and Breastfeeding
Pregnancy
- If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor, pharmacist, or nurse for advice before using this medicine.
- You must use effective contraception during treatment with Trazimera and for at least 7 months after treatment ends.
- Your doctor will advise you about the disadvantages and advantages of taking Trazimera during pregnancy. In rare cases, pregnant women treated with Trazimera have seen a reduction in the amount of (amniotic) fluid that surrounds the growing fetus in the womb. This condition can be harmful to your baby in the womb and has been associated with the lungs not developing fully resulting in fetal death.
Breast-feeding
Do not breastfeed your child during treatment with Trazimera and within 7 months after the last dose of Trazimera because Trazimera can pass to your child through breast milk.
Ask your doctor or pharmacist for advice before taking any medicine.
Driving ability and use of machinery
Trazimera may affect your ability to drive or use machines. If you experience symptoms such as dizziness, sleepiness, chills, or fever during treatment, you should not drive or operate machinery until these symptoms have disappeared.
Trazimera contains trastuzumab
How to get Trazimera
Before starting treatment, your doctor will determine whether your tumor is HER2-positive. Only patients with HER2 -positive cancer (high amounts of HER2 ) will be treated with Trazimera.
Trazimera should only be given by a doctor or nurse. Your doctor will prescribe the right dose and treatment regimen for you. The dose of Trazimera depends on your body weight.
Trazimera for intravenous use is not intended for subcutaneous use (under the skin) and should only be given as an intravenous infusion.
Trazimera for intravenous use is given as an intravenous infusion (“drip”) directly into a blood vessel. The first dose is given over 90 minutes and you will be observed by healthcare professionals while you receive the infusion in case you experience any side effects. If the first dose is well tolerated, the subsequent dose can be given within 30 minutes (see section 2 under “Warnings and precautions”). The number of infusions you receive depends on how you respond to treatment. Your doctor will discuss this with you.
To prevent medication errors, it is important to check the vial labeling to ensure that the drug being prepared and administered is Trazimera (trastuzumab) and not another product containing trastuzumab (eg, trastuzumab emtansine or trastuzumab deruxtecan).
In early breast cancer, metastatic breast cancer, and metastatic stomach cancer, Trazimera is given every three weeks. Trazimera can also be given once a week in metastatic breast cancer.
If you stop using Trazimera
Do not stop using this medicine without talking to your doctor first. All doses should be taken at the correct time each week or every three weeks (depending on your dosing interval). This helps the medicine work as well as possible.
It can take up to 7 months for Trazimera to disappear from the body. Therefore, your doctor may decide to continue to monitor your heart function even after treatment has ended.
If you have any further questions about this medicine, ask your doctor, pharmacist, or nurse.
Possible side effects
Like all medicines, Trazimera can cause side effects, although not everybody gets them. Some of these side effects can be serious and lead to hospitalization.
During an infusion with Trazimera, chills, fever and other flu-like symptoms may occur. These side effects are very common (may affect more than 1 in 10 patients). Other symptoms caused by infusion one are nausea, vomiting, pain, increased muscle tension and tremors, headache, dizziness, difficulty breathing, high or low blood pressure, altered heart rhythm (palpitations, fluttering or irregular heartbeat), swelling of the face and lips, skin rash and weakness. Some of these symptoms can be serious and some patients have died (see section 2 under “Warnings and precautions”).
These effects mainly occur in connection with the first intravenous infusion (the “drip”) and during the first hours after the start of the infusion. They are usually temporary. You will be monitored by healthcare professionals during the infusion and for at least six hours after the start of the first infusion and one and two hours after the start of the other infusions. If you develop symptoms, the healthcare professional will slow down or stop the infusion and they may give you treatment to counteract the side effects. After the improvement of the symptoms, the infusion can be continued.
Sometimes symptoms may occur later than six hours after the infusion is started. If this happens to you, contact your doctor immediately. Sometimes the symptoms may improve and later worsen.
Serious side effects are
Other side effects can occur at any time during treatment with Trazimera and are not related to the infusion itself. Tell a doctor or nurse immediately if you notice any of the following side effects:
- Heart problems can sometimes occur during treatment and sometimes after treatment has ended and can be serious. They include weakening of the heart muscle which can eventually lead to heart failure, inflammation around the heart, and altered heart rhythm. This can lead to symptoms such as shortness of breath (including shortness of breath during the night), cough, fluid retention (swelling) in the legs or arms, and palpitations (fluttering or irregular heartbeats) (see section 2. Monitoring the heart).
Your doctor will regularly check your heart during and after treatment, but you should tell your doctor immediately if you experience any of the above symptoms.
- Tumor lysis syndrome (a group of metabolic complications that occur after cancer treatment and are characterized by high levels of potassium and phosphate in the blood and low levels of calcium in the blood). Symptoms may include kidney problems (weakness, shortness of breath, tiredness, and confusion), heart problems (palpitations or a faster or slower heartbeat), seizures, vomiting or diarrhea, and tingling in the mouth, hands, or feet.
If you experience any of the above symptoms after stopping treatment with Trazimera, you should consult your doctor and tell the doctor that you have previously been treated with Trazimera.
Very common: may affect more than 1 in 10 people
- infection _
- diarrhea
- constipation
- heartburn ( dyspepsia )
- fatigue
- rash
- chest pain
- abdominal pain
- joint pain
- low levels of red blood cells and white blood cells (which help fight infection ) sometimes with fever
- muscle pain
- conjunctivitis (inflammation of the conjunctiva of the eye)
- watery eyes
- nosebleed
- runny nose
- hair loss
- tremors
- hot flashes
- dizziness
- nail changes
- weight loss
- loss of appetite
- insomnia _ _
- taste changes
- decreased number of platelets
- bruises
- numbness or tingling in the fingers and toes, which can sometimes spread to the rest of the arm or leg
- redness, swelling, or sores in the mouth and/or throat
- pain, swelling, redness, or tingling in the hands and/or feet
- shortness of breath
- headache
- cough
- vomiting
- nausea.
Common: may affect up to 1 in 10 people
| allergic reaction throat infections infection in the bladder and on the skin breast inflammation inflammation of the liver-kidney damage increased muscle tone or tension (hypertonus)pain in arms and/or legs itchy rashsleepiness ( somnolence )hemorrhoidsitchingdry mouth and skin | dry eyes sweating feeling of weakness and malaiseconcernDepressionasthmapneumonialung impact back pain neck pain bone painacneleg cramps |
Uncommon: may affect up to 1 in 100 people
- deafness
- bumpy skin rash
- wheezing/wheezing
- inflammation or scarring of the lungs
Rare: may affect up to 1 in 1,000 people
- jaundice
- anaphylactic reactions
Has been reported: occurring in an unknown number of users
- abnormal or impaired blood clotting
- high potassium levels
- swelling or bleeding inside the eye
- shock
- abnormal heart rhythm
- respiratory distress
- breathing problems
- acute accumulation of fluid in the lungs
- acute narrowed airways
- abnormally low oxygen content in the blood
- difficulty breathing when lying down
- liver damage
- swelling of the face, lips, and throat
- kidney failure
- abnormally little amniotic fluid around the fetus in the womb
- underdeveloped lungs of the fetus in the womb
- abnormal development of the kidneys of the fetus in the womb.
Some of the side effects you experience may be due to your underlying disease cancer. If you are treated with Trazimera together with chemotherapy, some of the side effects may also be due to the chemotherapy.
If you get side effects, talk to your doctor, pharmacist, or nurse.
How to store Trazimera
Keep this medicine out of the sight and reach of children.
Use before the expiry date which is stated on the outer carton (EXP) and the vial label (EXP). The expiration date is the last day of the specified month.
Store in a refrigerator (2 °C–8 °C).
Store in the original packaging. Light sensitive.
Unopened vials of Trazimera can be stored at up to 30 o C for a single period of no more than 3 months. Once Trazimera has been removed from the refrigerator, Trazimera must not be put back. Discard the product after these 3 months or when the expiry date stated on the vial has been reached, whichever occurs first. Record the date “To be discarded” in the date field on the carton.
Infusion solutions must be used immediately after preparation. Do not use Trazimera if you see particles or discoloration before administration.
The medicine must not be thrown into the drain or among the household waste. Ask the pharmacist how to deal with medicines that are no longer used. These measures will help to protect the environment.
Contents of the packaging and other information
Contents declaration
- The active substance is trastuzumab. A vial contains either:
- 150 mg of trastuzumab to be dissolved in 7.2 ml of sterile water for injections, or
- 420 mg of trastuzumab to be dissolved in 20 ml of sterile water for injections. The reconstituted solution contains approximately 21 mg/ml of trastuzumab.
- Other ingredients are L-histidine hydrochloride monohydrate, L-histidine, sucrose, and polysorbate 20 (E 432).
Appearance and package sizes of the medicine
Trazimera is a powder for concentrate solution for infusion supplied in a glass vial with a rubber stopper and contains either 150 mg or 420 mg of trastuzumab. The powder is in the form of a white cake. Each carton contains 1 vial of powder.
Marketing Authorisation Holder
Pfizer Europe MA EEIG
Boulevard de la Plaine 17
1050 Brussels
Belgium
Manufacturer
Pfizer Manufacturing Belgium NV
Rijksweg 12
2870 Puurs
Belgium
Contact the representative of the Marketing Authorization Holder if you would like to know more about this medicine:
| België/Belgique/BelgienLuxembourg/LuxembourgPfizer NV/SATel/Tel: +32 (0)2 554 62 11 | CyprusPfizer Ελλάς AE (Cyprus Branch)Phone: +357 22817690 |
| Czech RepublicPfizer, coil. s iPhone: +420 283 004 111 | MagyarországPfizer Kft.Tel.: +36 1 488 37 00 |
| DenmarkPfizer ApSPhone: +45 44 20 11 00 | MaltaDrugsales LtdPhone: +356 21419070/1/2 |
| DeutschlandPFIZER PHARMA GmbHPhone: +49 (0)30 550055-51000 | The NetherlandsPfizer by phone: +31 (0)10 406 43 01 |
| BulgariaPfizer Luxembourg САРЛ, Clone Bulgaria phone: +359 2 970 4333 | NorwayPfizer iPhone: +47 67 52 61 00 |
| EstoniaPfizer Luxembourg SARL Eesti branch phone: +372 666 7500 | AustriaPfizer Corporation Austria Ges.mbHPhone: +43 (0)1 521 15-0 |
| GreecePfizer Hellas iPhone: +30 210 6785800 | PolishPfizer Polska Sp. z o. oTel.: +48 22 335 61 00 |
| SpainPfizer, SLPhone: +34 91 490 99 00 | PortugalLaboratórios Pfizer, Lda.Phone: +351 21 423 5500 |
| FrancePfizerTel: + 33 (0)1 58 07 34 40 | RomaniaPfizer Romania SRLPhone: +40 (0) 21 207 28 00 |
| HrvatskaPfizer Croatia dooPhone: +385 1 3908 777 | SlovenijaPfizer Luxembourg SARLPfizer, branch of the fieldpharmacistactivities, LjubljanaPhone: +386 (0)1 52 11 400 |
| IrelandPfizer Healthcare IrelandTel: +1800 633 363 (toll free)Phone: +44 (0)1304 616161 | Slovenian RepublicPfizer Luxembourg SARL, organizačná zložkaPhone: +421 2 3355 5500 |
| IcelandIcepharma hf.Telephone: +354 540 8000 | Finland/FinlandPfizer OyPhone/Tel: +358 (0)9 430 040 |
| ItalyPfizer SrlPhone: +39 06 33 18 21 | SwedenPfizer ABPhone: +46 (0)8 550 520 00 |
| LatviaPfizer Luxembourg SARL branch in LatviaPhone: +371 670 35 775 | United Kingdom (Northern Ireland)Pfizer LimitedPhone: +44 (0)1304 616161 |
| LithuaniaPfizer Luxembourg SARL branches in LithuaniaPhone: +370 5 251 4000 |